文献速递白血病造血干细胞移植与细胞治疗

酪氨酸激酶抑制剂时代慢性髓性白血病急变期患者的管理与结局——欧洲白血病网急变期登记分析

Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry.
PubMed 文献 · Leukemia · 2024-03-28

该研究分析了欧洲白血病网急变期登记中2015年后诊断为慢性髓性白血病急变期患者的临床表现、治疗与结局。中位总生存期为23.8个月(中位随访27.8个月)。异基因造血干细胞移植可提高深度分子学缓解率。原发急变与继发急变特征略有不同,提示两者生物学存在差异。

要点

  • 中位总生存期23.8个月(中位随访27.8个月)。
  • 异基因造血干细胞移植可提高深度分子学缓解率。
  • 原发急变与继发急变特征略有不同,提示生物学差异。

核心结论

  • 在临床试验之外的真实世界中,急变期治疗根据疾病和患者特征个体化,目标是在异基因造血干细胞移植前清除原始细胞。
  • 所有适合该操作的患者均应接受异基因造血干细胞移植。

研究设计与样本

  • 欧洲白血病网急变期登记是一项国际性收集,纳入2015年后诊断为慢性髓性白血病急变期患者的临床表现、治疗和结局。

主要发现

  • 中位总生存期为23.8个月(中位随访27.8个月)。
  • 异基因造血干细胞移植提高深度分子学缓解率。
  • 原发急变与继发急变特征略有不同,提示两者生物学不同。

临床怎么用

  • 在临床试验之外的真实世界中,治疗根据疾病和患者特征个体化,目标是在异基因造血干细胞移植前清除原始细胞。
  • 所有适合该操作的患者均应接受异基因造血干细胞移植。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015. Data reveal the expected heterogeneity of the entity, lacking a clear treatment standard. Outcomes remain dismal, with a median overall survival of 23.8 months (median follow up 27.8 months). Allogeneic stem cell transplantation (alloSCT) increases the rate of deep molecular responses. De novo BP and BP evolving from a previous CML do show slightly different features, suggesting a different biology between the two entities. Data show that outside clinical trials and in a real-world setting treatment of blast phase is individualized according to disease- and patient-related characteristics, with the aim of blast clearance prior to allogeneic stem cell transplantation. AlloSCT should be offered to all patients eligible for this procedure.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Brioli A, Lomaia E, Fabisch C, et al. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era - analysis of the European LeukemiaNet Blast Phase Registry. Leukemia. 2024. PMID: 38548962. doi:10.1038/s41375-024-02204-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。